Krzysztof Gawrychowski

Krzysztof Gawrychowski

Auto-generated profile, based on publicly available information

Krzysztof Gawrychowski

Med Univ Warsaw, Dept Appl Pharm, Fac Pharm, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
AZAgnieszka Zajkowska
Agnieszka Zajkowska
MCMilena Czajka
Milena Czajka
KGKrystian Gulik
Krystian Gulik
KGKrzysztof Gawrychowski
Krzysztof Gawrychowski
MMMaciej Malecki
Maciej Malecki
Background. Despite the wide range of diagnostic and therapeutic methods, breast cancer is responsible for many deaths each year. One of the original and novel cancer therapeutic approaches is gene therapy based on recombinant adeno-associated viral vectors. Among the molecular factors with the potential to become useful diagnostic biomarkers, microRNA (miRNA) molecules are being considered for personalized therapies. Objectives. The aim of the study was to examine the utility of miRNA profiling in the design of personalized recombinant adeno-associated virus (rAAV)-based gene therapy for breast cancer patients. Materials and methods. The analysis of 754 miRNAs in 7 breast cancer samples and control samples was performed using real-time polymerase chain reaction (PCR) based on TaqMan (R) Low-density Array (TLDA) cards. Online repositories were used to explore the relationship between miRNAs and genes encoding rAAV receptors (KIAA0319L, HSPG2, FGFR1, c-MET, PDGFRA, ITGB5, and RPSA). Then, we performed a comparative analysis of the results to examine the possibility of using miRNA profiling in the design of rAAV-based therapeutic protocols. Results. Fifty-two percent of tested miRNAs were noted in at least 1 analyzed breast cancer and control tissue. Thirteen miRNAs were selected due to being outliers in the tested samples. In total, 155 miRNAs targeted genes encoding rAAV receptors in the tested samples (29 miRNAs for KIAA0319L, 60 miRNAs for c-MET, 31 miRNAs for HSPG2, 43 miRNAs for FGFR1, 36 miRNAs for PDGFRA, 18 miRNAs for RPSA, and 25 miRNAs for ITGB5). The expression of the selected miRNAs was not homogeneous across the 7 samples. Conclusions. Profiling of microRNA could be a significant factor in the design of rAAV-based personalized gene therapy for breast cancer patients.

1 January 2020 in Farmacja Polska
Verified
Journal Article
Open access
ŻSŻaneta Słyk
Żaneta Słyk
PKPaulina Kruk
Paulina Kruk
SBSławomir Barszcz
Sławomir Barszcz
KGKrzysztof Gawrychowski
Krzysztof Gawrychowski
MMMaciej Malecki
Maciej Malecki

27 April 2020 in Farmacja Polska
Verified
Journal Article
Closed access
ABAlicja Bieńkowska-Tokarczyk
Alicja Bieńkowska-Tokarczyk
IOIga Osińska
Iga Osińska
JNJoanna Nowosielska
Joanna Nowosielska
ALArkadiusz Leloch
Arkadiusz Leloch
KGKrzysztof Gawrychowski
Krzysztof Gawrychowski
MMMaciej Malecki
Maciej Malecki